02:39am Sunday 22 October 2017

Scientists discover new treatment for chronic pain condition

CRPS is an unexplained chronic pain condition that usually develops after an injury or trauma to a limb, and continues after the injury has healed.  CPRS I – formerly called Reflex Sympathetic Dystrophy – can arise after any type of injury.  CRPS II, previously called causalgia (a term coined in the American Civil War when it was first diagnosed), follows partial damage to a nerve.  In some cases the pain can be so severe that patients request amputation, only to find that the pain returns in the stump.

CRPS pain can improve within one year after the injury, but if it is still unchanged after 12 months (longstanding CRPS), then it will often not improve at all. Longstanding CRPS affects about 1 in 5,000 people in the UK.

The team at the Pain Research Institute discovered that a single, low dose infusion of intravenous immunoglobin (IVIG) significantly reduced pain in just under 50 per cent of patients treated, with few adverse effects. The pain relief lasted on average 5 weeks. The results of this study may change the future treatment of patients with CRPS, and have an impact on research in other severe chronic pain areas.  Intravenous immunoglobulin treatment for CRPS is currently not available on the NHS.
 
Although the cause of the syndrome is unknown, precipitating factors include injury or damage to the body’s tissue.  Changes in the way nerves send messages to the brain about pain may occur at the injury site.  These changes may then lead to more changes in the nerves of the spinal chord and brain.  All these changes are thought to play a role in causing and prolonging the condition.  Conventional pain drugs either don’t work, or have considerable side effects. 

Dr Goebel, Senior Lecturer in Pain Medicine, explains: “n CRPS, the real effect of this treatment in clinic may turn out to be even greater than what we have already seen, because IVIG can be given in higher doses, and repeated treatment may have additional effects.  IVIG is normally repeated every four weeks and we are working to develop ways which would allow patients to administer the treatment in their own home.”

“The discovery is expected to have a real impact on the treatment of other unexplained chronic pain conditions; if one pain condition can be effectively treated with an immune drug, then it is possible that other types will also respond.”

The research is published in the journal Annals of Internal Medicine.

Notes to editors:

1. The research was carried out in collaboration with University College London.

2. Research activities on the role of the immune system in chronic pain are the focus of the newly created ‘Centre for Immune Studies in Pain’ (CISP) at the University of Liverpool, led by Dr. Goebel. For further details visit www.liv.ac.uk\pri\cisp. Support for these and other research activities aimed at relieving chronic pain comes from the Pain Relief Foundation in Liverpool, www.painrelieffoundation.org.uk.

3. The University of Liverpool is a member of the Russell Group of leading research-intensive institutions in the UK. It attracts collaborative and contract research commissions from a wide range of national and international organisations valued at more than £97 million annually.

Contact us:

Kate Spark

Media Relations Manager

Phone: work +44 (0) 151 794 2247
Out of hours (cell+44 (0) 7970 247391)

Samantha Martin

Senior Press Officer

Phone: work +44 (0) 151 794 2248
Out of hours (cell+44 (0) 7973 247836)

Sarah Stamper

Press and Marketing Officer

Phone: work +44 (0) 151 794 3044
Out of hours (cell+44 (0) 7970 247396)


Share on:
or:

MORE FROM Surgery and Rehabilitation

Health news